Alan Sandler

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. ncbi request reprint Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
  2. pmc A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group
    Leora Horn
    Department of Hematology Oncology, Vanderbilt University, Nashville, Tennessee, USA
    J Thorac Oncol 4:527-33. 2009
  3. ncbi request reprint Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
    Jeffrey M Albert
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Cancer Res 13:3033-42. 2007
  4. ncbi request reprint Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib
    Alan Sandler
    Division of Hematology Oncology, Vanderbilt University, Medical Center, Nashville, Tennessee, USA
    Oncology (Williston Park) 17:17-22. 2003
  5. ncbi request reprint Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways
    Alan Sandler
    Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6307, USA
    Clin Cancer Res 12:4421s-4425s. 2006
  6. ncbi request reprint Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel
    Ildiko Csiki
    Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
    Clin Cancer Res 11:6634-40. 2005
  7. doi request reprint A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer
    Leora Horn
    Vanderbilt Ingram Cancer Center, Nashville, TN, USA
    Clin Lung Cancer 12:161-5. 2011
  8. ncbi request reprint Bevacizumab in non small cell lung cancer
    Alan Sandler
    Thoracic Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6307, USA
    Clin Cancer Res 13:s4613-6. 2007
  9. ncbi request reprint Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer
    Jeffrey M Albert
    Department of Radiation Oncology, Vanderbilt University, 1301 Medical Center Drive, B 902 The Vanderbilt Clinic, Nashville, TN 37232 5671, USA
    Cancer Epidemiol Biomarkers Prev 16:1845-51. 2007
  10. ncbi request reprint Irinotecan plus cisplatin in small-cell lung cancer
    Alan Sandler
    Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5536, USA
    Oncology (Williston Park) 16:39-43. 2002

Collaborators

Detail Information

Publications44

  1. ncbi request reprint Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  2. pmc A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group
    Leora Horn
    Department of Hematology Oncology, Vanderbilt University, Nashville, Tennessee, USA
    J Thorac Oncol 4:527-33. 2009
    ....
  3. ncbi request reprint Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models
    Jeffrey M Albert
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    Clin Cancer Res 13:3033-42. 2007
    ..Ionizing radiation induces DNA strand breaks, suggesting that PARP-1 inhibition may sensitize tumor cells to radiation...
  4. ncbi request reprint Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib
    Alan Sandler
    Division of Hematology Oncology, Vanderbilt University, Medical Center, Nashville, Tennessee, USA
    Oncology (Williston Park) 17:17-22. 2003
    ..The phase III BR.21 trial is assessing erlotinib monotherapy in advanced refractory non-small-cell lung cancer. Results of these phase II trials will soon be available...
  5. ncbi request reprint Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways
    Alan Sandler
    Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6307, USA
    Clin Cancer Res 12:4421s-4425s. 2006
    ..Encouraging antitumor activity and safety of erlotinib plus bevacizumab support further development of this combination for patients with advanced NSCLC. A randomized phase II trial has been completed, and a phase III trial is ongoing...
  6. ncbi request reprint Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel
    Ildiko Csiki
    Department of Cancer Biology, Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
    Clin Cancer Res 11:6634-40. 2005
    ..However, in light of the apparent survival prolongation in the subset with a marked decline in urinary PGE-M levels, further investigation of strategies designed to decrease PGE(2) synthesis in NSCLC seems warranted...
  7. doi request reprint A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer
    Leora Horn
    Vanderbilt Ingram Cancer Center, Nashville, TN, USA
    Clin Lung Cancer 12:161-5. 2011
    ..Secondary objectives included progression-free survival (PFS), overall survival, and toxicity findings...
  8. ncbi request reprint Bevacizumab in non small cell lung cancer
    Alan Sandler
    Thoracic Oncology, Vanderbilt Ingram Cancer Center, Nashville, Tennessee 37232 6307, USA
    Clin Cancer Res 13:s4613-6. 2007
    ..Future and current directions include evaluation of bevacizumab in earlier stages of NSCLC, in SCLC, and in combination with other targeted agents, such as erlotinib...
  9. ncbi request reprint Cytoplasmic clusterin expression is associated with longer survival in patients with resected non small cell lung cancer
    Jeffrey M Albert
    Department of Radiation Oncology, Vanderbilt University, 1301 Medical Center Drive, B 902 The Vanderbilt Clinic, Nashville, TN 37232 5671, USA
    Cancer Epidemiol Biomarkers Prev 16:1845-51. 2007
    ..Previous studies have examined the prognostic value of clusterin expression in various malignancies. In the present study, we examined clusterin staining in tumors resected from patients with non-small cell lung cancer (NSCLC)...
  10. ncbi request reprint Irinotecan plus cisplatin in small-cell lung cancer
    Alan Sandler
    Division of Medical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee 37232 5536, USA
    Oncology (Williston Park) 16:39-43. 2002
    ..This article will review the use of irinotecan in combination with cisplatin in patients with small-cell lung cancer...
  11. pmc Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer
    Leora Horn
    Vanderbilt Ingram Cancer Centre, Division of Hematology Oncology, Nashville, Tennessee, USA
    Clin Cancer Res 15:5040-8. 2009
    ..In this article we review clinical data for molecular-targeted therapies in NSCLC, with emphasis on EGFR inhibitors and antiangiogenic agents...
  12. doi request reprint Identifying barriers associated with enrollment of patients with lung cancer into clinical trials
    Leora Horn
    Vanderbilt Ingram Cancer Center, Nashville, TN 37232, USA
    Clin Lung Cancer 14:14-8. 2013
    ..Enrollment of patients with lung cancer into clinical trials is required to accelerate the pace of new therapy development and contribute to a better understanding of the biological characteristics of cancer...
  13. pmc VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
    David P Carbone
    Vanderbilt University Medical Center, 685 PRB, 2220 Pierce Avenue, Nashville, TN 37232, United States
    Lung Cancer 69:337-40. 2010
    ..We found that VeriStrat could classify these patients into two groups with significantly better or worse outcomes and may enable rational selection of patients more likely to benefit from this costly and potentially toxic regimen...
  14. pmc Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer
    Philip E Lammers
    Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee Department of Biostatistics, Center for Quantitative Science, Vanderbilt University Medical Center, Nashville, Tennessee South Carolina Oncology Associates, Columbia, South Carolina Department of Medicine, Division of Hematology and Medical Oncology, Oregon Health and Science University, OHSU Knight Cancer Institute, Portland, Oregon Department of Medicine, Division of Medical Oncology, The Ohio State University Medical Center, Arthur G James Cancer Hospital, Columbus, Ohio Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas and Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Vanderbilt Ingram Cancer Center, Nashville, Tennessee
    J Thorac Oncol 9:559-62. 2014
    ..To determine the time to progression (TTP), response rate (RR), and toxicity for North American patients with relapsed small-cell lung cancer (SCLC) treated with bendamustine in the second- or third-line setting...
  15. ncbi request reprint State-of-the-art treatment for advanced non-small-cell lung cancer
    Alan Sandler
    Division of Hematology and Oncology, Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA
    Oncology (Williston Park) 17:15-22. 2003
    ....
  16. ncbi request reprint Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer
    Carolyn Cao
    Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232 5671, USA
    Cancer Res 66:11409-15. 2006
    ..Clinical trials are needed to determine the potential of this combination therapy in patients with locally advanced lung cancer...
  17. ncbi request reprint Irinotecan therapy for small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Medical Center, Nashville, Tennessee 37232, USA
    Oncology (Williston Park) 16:419-25, 428, 433; discussion 433-4, 437-8. 2002
    ....
  18. pmc Development of clinical trials in a cooperative group setting: the eastern cooperative oncology group
    David M Dilts
    Owen Graduate School of Management and Engineering Management Program, School of Engineering, Vanderbilt University, 401 21st Avenue South, Nashville, TN 37203, USA
    Clin Cancer Res 14:3427-33. 2008
    ..Calendar time was collected for each major process for each study in this set...
  19. ncbi request reprint A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer
    Sumeet Bhatia
    Indiana University, 535 Barnhill Drive Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 38:73-7. 2002
    ..In conclusion, weekly gemcitabine with paclitaxel in patients with advanced NSCLC is an active regimen; however, toxicity and poor survival precludes the use of this regimen as an experimental arm on a future phase III study...
  20. ncbi request reprint Chemotherapy and antiangiogenic agents in non-small-cell lung cancer
    Leora Horn
    Department of Medicine, University of Toronto, ON, Canada
    Clin Lung Cancer 8:S68-73. 2007
    ..Future directions will include the use of these agents in combination with one another as well as in combination with chemotherapy and radiation therapy in patients with early-stage (IA-IIIB) disease...
  21. ncbi request reprint Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer
    Roy S Herbst
    The M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 25:4743-50. 2007
    ..A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile...
  22. doi request reprint The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib
    Mary J Fidler
    Rush University Medical Center, Chicago, Illinois 60612, USA
    Clin Cancer Res 14:2088-94. 2008
    ..With these observations, we designed a phase II trial to evaluate the efficacy and safety of erlotinib plus celecoxib in advanced NSCLC...
  23. ncbi request reprint Angiogenesis inhibition in the treatment of lung cancer
    Everett Vokes
    University of Chicago, Chicago, IL, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Ongoing studies are continuing to investigate new agents and identify the patients most likely to benefit from antiangiogenic therapy...
  24. ncbi request reprint Lung cancer adjuvant therapy
    Leora Horn
    Department of Medicine, University of Toronto, Toronto, ON, Canada
    Cancer J 13:210-6. 2007
    ..In this article, we review the rationale and evidence for neoadjuvant and adjuvant therapy with chemotherapy, radiation therapy, and combined modality therapy in patients with resected non-small cell lung cancer...
  25. ncbi request reprint Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer
    Nasser Hanna
    Indiana University, Indianapolis, IN 46202, USA
    J Clin Oncol 24:2038-43. 2006
    ..Our trial was designed to determine if a modified weekly regimen of IP would provide superior survival with less toxicity than EP...
  26. ncbi request reprint Etoposide, ifosfamide and cisplatin (VIP) plus concurrent radiation therapy for previously untreated limited small cell lung cancer (SCLC): a Hoosier Oncology Group (HOG) phase II study
    Nasser Hanna
    Department of Medicine, Indiana University, 535 Barnhill Drive, Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 35:293-7. 2002
    ..In addition, treatment-related morbidity and mortality appears to be unacceptably high with the VIP regimen...
  27. ncbi request reprint Lung cancer in the elderly: current and future chemotherapeutic options
    Stuart Hinton
    Indiana University School of Medicine, Indianapolis, Indiana, USA
    Drugs Aging 19:365-75. 2002
    ..Given the prevalence of the disease, future studies need to include an appropriate number of elderly patients with continued emphasis on quality of life in addition to survival...
  28. ncbi request reprint Carboplatin plus paclitaxel and sequential radiation followed by consolidation carboplatin and paclitaxel in patients with previously untreated locally advanced NSCLC. A Hoosier Oncology Group (HOG) phase II study
    Sumeet Bhatia
    Department of Medicine, Indiana University, 535 Barnhill Drive Room 473, Indianapolis, IN 46202, USA
    Lung Cancer 38:85-9. 2002
    ..5 months, 45, and 17%, respectively. In conclusion, consolidation chemotherapy was associated with significant hematologic toxicity without an obvious improvement in survival in comparison to other studies utilizing chemoradiation alone...
  29. ncbi request reprint Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer
    Vincent A Miller
    Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 21:2094-100. 2003
    ..This pilot trial combined gefitinib with carboplatin and paclitaxel to define the toxicities of the combination and assess drug-drug interactions in untreated advanced NSCLC patients...
  30. ncbi request reprint Ongoing and future trials of biologic therapies in lung cancer
    Paul A Bunn
    University of Colorado Cancer Center, Denver, CO, USA
    Lung Cancer 41:S175-86. 2003
    ..Many new agents have been developed to attack these targets. This article describes current and proposed trials for these new targeted therapies in both small cell and non-small cell lung cancers...
  31. ncbi request reprint An advance in small-cell lung cancer treatment--more or less
    Janessa Laskin
    J Natl Cancer Inst 95:1099-101. 2003
  32. ncbi request reprint Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial
    Mark G Kris
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center and the Weill Medical College of Cornell University, New York, NY 10021, USA
    JAMA 290:2149-58. 2003
    ....
  33. ncbi request reprint Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
    Joan H Schiller
    University of Wisconsin Hospital and Clinics, Madison, USA
    N Engl J Med 346:92-8. 2002
    ..We conducted a randomized study to determine whether any of three chemotherapy regimens was superior to cisplatin and paclitaxel in patients with advanced non-small-cell lung cancer...
  34. ncbi request reprint Angiogenesis and lung cancer: prognostic and therapeutic implications
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030 4009, USA
    J Clin Oncol 23:3243-56. 2005
    ....
  35. ncbi request reprint TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
    Roy S Herbst
    University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 23:5892-9. 2005
    ..Erlotinib was combined with chemotherapy to determine if it could improve the outcome of patients with NSCLC...
  36. ncbi request reprint Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung canc
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, Biostatistics and Diagnostic Radiology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 23:2544-55. 2005
    ..Preclinical data in various xenograft models produced greater growth inhibition than with either agent alone. Additionally, both agents have demonstrated benefit in patients with previously treated non-small-cell lung cancer (NSCLC)...
  37. ncbi request reprint Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies
    Ramaswamy Govindan
    Washington University School of Medicine, St Louis, MO 63110, USA
    J Clin Oncol 24:4848-54. 2006
    ..To evaluate the effect of bexarotene on survival in patients with relapsed non-small-cell lung cancer (NSCLC)...
  38. ncbi request reprint Clinical utility of EUS-guided fine-needle aspiration of mediastinal masses in the absence of known pulmonary malignancy
    Benedict M Devereaux
    Indiana University Medical Center, Indianapolis, Indiana 46202, USA
    Gastrointest Endosc 56:397-401. 2002
    ..A large, single-center experience with EUS-guided fine-needle aspiration (EUS-FNA) in the diagnosis of non-lung cancer-related mediastinal masses is presented...
  39. ncbi request reprint Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer
    Christopher J Sweeney
    Indiana University Cancer Center, Indianapolis, IN, USA
    Clin Cancer Res 12:536-42. 2006
    ....
  40. ncbi request reprint Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597
    Gregory A Masters
    Helen Graham Cancer Center, 4701 Ogletown Stanton Rd, Ste 2200, Newark, DE 19713, USA
    J Clin Oncol 21:1550-5. 2003
    ..The objective of this phase II trial was to investigate the activity of gemcitabine in patients with relapsed SCLC...
  41. ncbi request reprint Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
    Alain C Mita
    Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX, 78229, USA
    J Clin Oncol 24:552-62. 2006
    ..This phase I study was conducted to determine the toxicities, pharmacokinetics, and recommended doses of pemetrexed in cancer patients with normal and impaired renal function...
  42. ncbi request reprint Phase I study of inhaled Doxorubicin for patients with metastatic tumors to the lungs
    Gregory A Otterson
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA
    Clin Cancer Res 13:1246-52. 2007
    ..To evaluate the toxicity profile of inhalational doxorubicin in patients with malignant disease in the lung...
  43. ncbi request reprint A Phase I trial of a potent P-glycoprotein inhibitor, zosuquidar trihydrochloride (LY335979), administered intravenously in combination with doxorubicin in patients with advanced malignancy
    Alan Sandler
    Department of Medicine, Section of Hematology Oncology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    Clin Cancer Res 10:3265-72. 2004
    ..v. over 48 h in a cohort-dose escalation manner until the occurrence of dose-limiting toxicity or protocol specified maximum exposure. Doxorubicin doses of 45, 60, 75 mg/m(2) were administered during the course of the trial...
  44. ncbi request reprint A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities
    Arno J Mundt
    University of Chicago Medical Center, Chicago, Illinois, USA
    Clin Cancer Res 10:5747-53. 2004
    ..The objective of this study was to assess the tolerance of combining TNFerade and radiation therapy in patients with soft tissue sarcomas of the extremity...